NAFLD is considered to cover a spectrum of disease activity. This spectrum begins as fatty accumulation in the liver (hepatic steatosis). A liver can remain fatty without disturbing liver function, but by varying mechanisms and possible insults to the liver may also progress to become non-alcoholic steatohepatitis (NASH), A total of 227 subjects were recruited, with NAFLD being diagnosed in 40% of the cohort. Although 71.2% subjects had heard about NAFLD before, only 25.4% of them felt that they were at risk of NAFLD. Comparable responses were observed in subjects with no metabolic risk factors relative to subjects with one or more metabolic risk factors (P > 0.05). Of note, 75.6% of subjects with one or more metabolic risk factors did not think that they were at risk of NAFLD.
Research is ongoing on many aspects of NAFLD, including pathophysiology and potential treatments. Additionally, multi-center pediatric trials are ongoing at the hospital, as part of the National Institutes of Health Non-Alcoholic Steatohepatitis Clinical Research Network.NAFLD can also be caused by some medications: Amiodarone, Antiviral drugs, Aspirin, Corticosteroids, Methotrexate, Tamoxifen, Tetracycline.